Morgan Stanley lowered the firm’s price target on Regeneron (REGN) to $756 from $761 and keeps an Overweight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study
- Regeneron says FDA approves PD-1 inhibitor Libtayo
- FDA approves Regeneron’s Libtayo for cutaneous squamous cell carcinoma
- Early notable gainers among liquid option names on October 1st
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 9/30/2025